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ABSTRACT
Centrosome amplification (CA), a cell-biological trait, characterizes pre-neoplastic
and pre-invasive lesions and is associated with tumor aggressiveness. Recent studies
suggest that CA leads to malignant transformation and promotes invasion in mammary
epithelial cells. Triple negative breast cancer (TNBC), a histologically-aggressive
subtype shows high recurrence, metastases, and mortality rates. Since TNBC and nonTNBC follow variable kinetics of metastatic progression, they constitute a novel test bed
to explore if severity and nature of CA can distinguish them apart. We quantitatively
assessed structural and numerical centrosomal aberrations for each patient sample in a
large-cohort of grade-matched TNBC (n = 30) and non-TNBC (n = 98) cases employing
multi-color confocal imaging. Our data establish differences in incidence and severity
of CA between TNBC and non-TNBC cell lines and clinical specimens. We found strong
correlation between CA and aggressiveness markers associated with metastasis in
20 pairs of grade-matched TNBC and non-TNBC specimens (p < 0.02). Time-lapse
imaging of MDA-MB-231 cells harboring amplified centrosomes demonstrated enhanced
migratory ability. Our study bridges a vital knowledge gap by pinpointing that CA
underlies breast cancer aggressiveness. This previously unrecognized organellar
inequality at the centrosome level may allow early-risk prediction and explain higher
tumor aggressiveness and mortality rates in TNBC patients.

breast cancer cases in pre-menopausal AA patients are TN
(5-year survival of ~80% as opposed to ~90% in European
American patients), putting this patient subgroup at a
higher risk for poorer outcomes [4].
Recent literature points out an intriguing correlation
between BRCA1 (breast cancer suppressor gene 1)
mutation carriers and TNBC status. About 70% of women
with breast cancer carrying a BRCA1 mutation belong to
the triple-negative subtype [5]. Beyond a crucial role of

INTRODUCTION
As the name foretells, triple-negative breast cancers
(TNBC) do not over-express the estrogen, progesterone,
or Her2 receptors, thus precluding patient response to
several targeted therapies available in the clinic. More so,
TNBC preferentially afflicts women of African descent
and is characterized by high aggressiveness, recurrence,
metastases and mortality rates [1–3]. About 40% of all
www.impactjournals.com/oncotarget
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BRCA1 in regulating centrosome duplication, BRCA1
is also known to interact with a variety of proteins that
regulate centrosome duplication, including BRCA2 (breast
cancer suppressor gene 2), CDK2/Cyclin A, CDK2/
Cyclin E, Gadd45, p21, p53 and Rb [6–8]. Furthermore,
targeted disruption of BRCA1 results in centrosome
amplification (CA), confirming that BRCA1 serves as
a negative regulator for centrosome duplication [9].
These data are consistent with the notion that BRCA1
and BRCA2 tumor suppressor genes directly maintain
genomic stability, and affirm a causative link between
BRCA1 mutations and centrosomal overload that is
associated with extensive chromosomal instability (CIN)
found in TNBC patients. Therefore, amplified centrosomes
may present a fascinating, readily quantifiable prognostic
marker and druggable target for TNBCs, currently plagued
by insufficiency of molecular targets that precludes their
treatment and optimal management.
Centrosomal abnormalities and CIN strongly
characterize pre-invasive in situ ductal carcinomas, thus
incriminating these anomalies in fueling tumor progression
and metastases. Thus far, a thorough quantitative
comparison of centrosomal aberrations in breast tumor
subtypes with inherently different metastatic capability has
never been reported. Herein, we performed a comprehensive
quantitative analysis of centrosomal abnormalities in
breast tumors to establish differences in incidence and
severity of CA (structural and numeral) between gradematched TNBC (n = 30) and non-TNBC (n = 98) patients.
Intriguingly, we found significant correlation of CA status
with patient outcomes wherein we ascertained that patients
exhibiting higher centrosome aberrations (> 20%) had
lower Progression free survival (PFS) than patients with
lower centrosome aberrations (< 20%). We also established
a strong association between CA markers and markers of
breast tumor aggressiveness, suggesting that robust CA
underlies acquisition of aggressive phenotypes.
Our results generate compelling foregrounds to
establish CA as a quantifiable property of low-grade tumors
that can predict the risk of a tumor being or becoming an
aggressive one. A validated method to quantify this cellbiological cancer-specific organellar trait can provide
clinicians with a method to stratify low-grade tumors into
high- and low-risk subgroups and may enable channeling
of patients into optimal treatment paths to reduce existing
disparities in breast cancer patient outcomes.

course. These studies however lacked rigorous quantitation
of the centrosomal abnormalities and have not explored
whether centrosomal abnormalities are accompanied by
any changes in the expression patterns of centrosomal
genes. Given that there are differences in aggressive
behavior between TNBC and non-TNBC patients, we
investigated whether these histologically-distinct breast
cancer subtypes might differ in the expression levels of
centrosomal genes. To this end, we mined publicallyavailable microarray data of breast cancer patients to
evaluate gene expression levels for major structural
centrosomal proteins, both centriolar (centrin) and
pericentriolar (pericentrin and γ-tubulin). To gain deeper
insights into centrosomal aberrations, we included
genes whose dysregulation is implicated in CA (pololike kinase 4 and cyclin E). We calculated a cumulative
gene expression-based centrosome amplification index
(CAI) by adding log transformed, normalized gene
expression for CETN2 (centrin-2), TUBG1 (γ-tubulin),
PCNT2 (pericentrin), PLK4 (polo-like kinase 4) and
CCNE1 (cyclin E) genes. Given that cancer is a clonally
evolving disease and CA could arise due to dysregulation
of different genes in different cancers and even distinct
cancer cell clones, we chose to select a panel of five
centrosomal genes instead of a single gene. First, we
evaluated the relationship of higher CA, as assessed by
CAI, with disease aggressiveness, as determined by
overall survival (OS). OS was calculated as the number
of days from diagnosis to death or last follow-up if death
was not recorded. Irrespective of receptor status (TNBC
n = 101, non-TNBC n = 61), patients with higher CAI
(n = 78) had lower OS (p = 0.049) than patients with lower
CAI (n = 84) (Fig. 1A). Intriguingly, high CAI group was
composed of ~60% TNBC cases whereas the low CAI
group composed of ~38% TNBC cases, thus indicating
that TNBCs tend to have higher CAI as compared to nonTNBCs. Further analysis of another dataset of 138 TNBC
and 466 non-TNBC samples clearly showed significantly
higher CAI in TNBCs compared to non-TNBCs, even
when they were (a) grade-matched (Fig. 1B), or (b) stagematched (Fig. 1C).
In sum, these data suggest that more aggressive
disease course in TNBC is accompanied by significant
overexpression of centrosomal genes. Additionally,
overexpression of centrosomal genes is strongly associated
with poorer OS.

RESULTS

TNBC patients have higher centrosome
amplification than non-TNBC

In silico overexpression of CA-associated genes
is correlated with reduced survival and triplenegative subtype

Our in silico data analysis yielded significantly
elevated CAI in TNBC women compared to non-TNBC.
Thus, we visualized amplified centrosomes in gradematched tissues from TNBC (n = 59) and non-TNBC
(n = 116) patients (Fig. 2A) employing multicolor
confocal immunofluorescence microscopy. Centrosomes

Previous studies in solid tumors have alluded to
an association between centrosomal abnormalities and
advanced disease, aneuploidy, and an aggressive clinical
www.impactjournals.com/oncotarget
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Figure 1: Breast tumors with higher CAI have lower survival rate compared to low CAI tumors. A. Overall survival
plots for high and low CAI groups. High CAI patients had lower overall survival (n = 84) compared to low CAI patients (n = 78) in in silico
data. B. Scatter-plot comparing the CAI in TNBC and grade-matched non-TNBC patients (p < 0.001 for Grade II TNBC and non-TNBC
patients). C. Bar graphs comparing the CAI in TNBC and non-TNBC patients considering stages (p < 0.005 for stage-matched TNBC
and non-TNBC patients). (Lower n number in the survival analysis is due to the limited availability of survival data for all patients in the
referred databases.)
patients. Immunoblotting of tissue lysates showed
higher expression of two centrosomal proteins (centrin-2
and γ-tubulin) in TNBC than in non-TNBC patients
(Fig. 3A). In addition, breast cancer cell lines derived
from TNBC patients (MDA-MB-468, MDA-MB-231)
showed (a) higher incidence and severity of centrosome
amplification (Fig. 3Ci, ii) (b) elevated expression
of centrosomal (pericentrin, centrin-2, γ-tubulin) and
centrosome amplification markers (Plk4 and cyclin E),
compared to non-TNBC-derived (MCF-7) lines (Fig. 3B).
Intriguingly, the extent of amplification was considerably
lower in cell lines (5–30%) compared to patient tissue
samples (15–80%), irrespective of the receptor status.
This observation highlights a previously unrecognized
discordance between human tumor tissues and established
cell lines. This also underscores the limitations of in vitro
cell lines as a model system for establishing and testing
centrosome-targeted therapies.

were labelled by γ-tubulin (green) antibody, wherein
centrosomal aberrations were determined by abnormal
number of γ-tubulin spots (more than two) as well as by
increased volume over normal centrosomal volume in
breast epithelial cells from normal adjacent tissues. Fig. 2A
shows representative confocal immunomicrographs
depicting centrosomes (γ-tubulin, green) and nuclei
(DAPI, blue) from normal breast tissue and breast cancer
tissue from grade-matched (Grade II) TNBC and nonTNBC patients. Cells with more than two centrosomes
were estimated by examining and counting centrosomes
in atleast 500 cells/slide. Fig. 2B shows that the number
of cells harboring extra centrosomes were twice as much
higher in TNBC samples (62, n = 30) versus non-TNBC
(30, n = 98) (p < 0.05) in a grade-matched background.
We next measured centrosomal volumes in all specimens
using the three-dimensional measurement module from
the Zeiss imaging software. While mean centrosomal
volume in normal breast epithelial cells was 0.22 μm3
(ranging from 0.08 to 0.76 μm3), the mean volume of
γ-tubulin-stained spots analyzed in at least 500 tumor
cells from each patient sample was 4.85 μm3, which is ~15
times higher than the centrosomal volume in normal cells.
Fig. 2C shows that centrosome volume was significantly
higher in TNBC samples (n = 30) (average = 6.8 μm3)
compared to grade-matched (Grade II) non-TNBC (n = 98)
samples (average = 4.2 μm3) (p < 0.05). Additionally,
we calculated the total centrosome amplification as a
percentage by adding percent cells harboring more than
two centrosomes and percent cells harboring centrosomes
with volume larger than 0.76 μm3. Our analysis revealed
that on an average, ~68% of cells in TNBC samples
exhibited centrosome amplification as compared to ~45%
in non-TNBC samples (p < 0.05).
We next compared the expression levels of
centrosomal proteins (centrin-2 and γ-tubulin) in freshfrozen tumors and uninvolved adjacent tissue from
20 pairs of grade-matched TNBC and non-TNBC
www.impactjournals.com/oncotarget

Centrosome amplification status correlates
strongly with metastatic disease and progressionfree survival in patient samples
We next evaluated expression levels of molecules
implicated in CA by immunohistochemical staining
of paraffin-embedded tumor and uninvolved adjacent
tissue in 20 pairs of grade-matched (Grade II) TNBC
and non-TNBC samples. Immunohistochemical data
strongly suggested overexpression of well-established
centrosome amplification markers (Aurora-A and Plk4) in
TNBC compared to non-TNBC samples (Fig. 4A). The
same samples were also immunostained for vimentin, a
breast cancer aggressiveness marker. As expected, TNBC
samples exhibited significantly higher expression of
vimentin (Fig. 4B). Representative images of two sets
of grade-matched breast tumor samples (one TNBC,
one non-TNBC) exhibiting different expression levels
of centrosomal proteins, show that TNBC samples
10489
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Figure 2: Comparison of extent of centrosome amplification in grade-matched TNBC and non-TNBC patients.

A. Representative confocal micrographs depicting the status of centrosome amplification in histological Grade I, Grade II and Grade III
TNBC and non-TNBC tissues. Centrosomes were labelled with γ-tubulin antibody (green) and DNA was stained with DAPI (blue) Yellow
arrows indicate numerical amplification and white arrows indicate structural amplification. Scale bar 5 μm. B. Bar graph representation
of number of cells out of 500 showing supernumerary centrosomes (> 2 or ≤ 2) in TNBC and non-TNBC tissue samples. C. Box whisker
graph representation of average volume of centrosomes in normal, TNBC and non-TNBC tissue samples. At least 500 cells were counted
in each case (ANOVA, p < 0.05).

exhibited higher expression levels of these proteins
than non-TNBC samples and normal tissue (Fig. 4A).
Statistical analysis of 20 pairs of grade-matched TNBC
and non-TNBC samples revealed a strong positive
correlation between Plk4 and vimentin (r = 0.58,
p < 0.02). Immunoblots shown in Fig. 4C also support
our observation that centrosomal markers (Aurora-A,
Plk4 and cyclin E) exhibit similar expression patterns and
trends as metastasis markers (vimentin) in breast tumor
samples. Furthermore, we evaluated the relationship of
higher centrosome aberrations (as assessed by %CA in
Fig. 2Bi) with progression-free survival (PFS) in breast
cancer patients. PFS was calculated as the number of days
from diagnosis to the first local recurrence or metastasis
(if one occurred), or the last follow-up if the patient did
not progress. Irrespective of receptor status (n = 120),
www.impactjournals.com/oncotarget

patients with higher centrosome aberrations (> 20%) had
lower PFS (p < 0.08) than patients with lower centrosome
aberrations (< 20%) (Fig. 4D). Interestingly, a majority
(~72%) of high CA (high-risk) group were TNBC while
low CA (low-risk) group were largely non-TNBC (~60%).

Cells with supernumerary centrosomes
show higher migration velocity and net
displacement compared to cells with
normonumerary centrosomes
We next asked if extra centrosomes were
associated with enhanced cell migration. To discern
this, we performed a cell migration assay using timelapse imaging wherein migration of MDA-MB-231 cells
(stably transfected with GFP-tagged centriolar protein,
10490
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Figure 3: TNBC tumors and cell lines show higher expression of centrosomal markers. A. Immunoblots for 5 paired
breast tumor (T) and normal adjacent (N) tissues from grade-matched TNBC and non-TNBC patients showing expression levels of
centrosomal markers. B. Immunoblots of centrosomal markers in MCF-7 (non-TNBC), MDA-MB-468 and MDA-MB-231 (TNBC) cell
lines. Ci. Immunofluorescence micrographs showing MCF-10A cells (near-normal), MCF-7 cells (non-TNBC) and MDA-MB-468 and
MDA-MB-231 cells (TNBC) in interphase and mitotic state, stained for γ-tubulin (green), α-tubulin (red) and DAPI (blue). Cii. Bar graph
quantitation of percent cells depicting multipolar mitosis and centrosomal amplification in interphase in MCF-7 (non-TNBC) and MDAMB-468 and MDA-MB-231 (TNBC) cell lines. (Only Grade II TNBC and non-TNBC samples were matched because of limited n numbers
for Grade I TNBC and Grade III non-TNBC samples in our dataset.)

Figure 4: Breast tumors in TNBC patients show higher expression of centrosomal proteins and aggressiveness
markers. A. Micrographs showing immunohistchemical staining for Aurora-A, Plk4 (centrosomal amplification markers) and vimentin

(breast cancer metastasis marker) in normal and cancer tissue from representative grade-matched TNBC (2170) and non-TNBC (6456)
patients. B. Box whisker graph showing significantly higher expression of vimentin in TNBC samples when compared to grade-matched
non-TNBC samples. C. Immunoblots for normal, TNBC (2170) and non-TNBC (6456) tissue samples showing Aurora-A, Cyclin E and
vimentin expression. D. Progression free survival (PFS) plot for the patients with higher (> 20%) CA (red) and lower (< 20%) CA (blue).
(Only Grade II TNBC and non-TNBC samples were matched because of limited n numbers for Grade I TNBC and Grade III non-TNBC
samples in our dataset.)
www.impactjournals.com/oncotarget
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centrin) harboring 1 centrosome or > 2 centrosomes
was observed. Fig. 5A shows representative data for
a pair of cells observed upon 18 h time-lapse imaging,
where a cell with 1 centrosome migrated from a to a’
(Fig. 5Ai) and a cell with 4 centrosomes moved from
b to b’ (Fig. 5Aii). Quantitation of merged time-lapse
sequences (10 min apart, collected over 18 h) showed
higher average net displacement (78%), displacement
rate (55%) and track velocity (~2 fold enhancement)
of cells with > 2 centrosomes compared to cells with
1 centrosome (Fig. 5Bi,ii,iii). These data strongly suggest
that overabundance of centrosomes enhances migratory
ability in cancer cells. Having established a strong
correlation between extra centrosomes and cell migration
in MDA-MB-231, an aggressive breast cancer cell line,
we next asked if centrosome amplification directly and
independently impacted the migration potential of a nearnormal immortalized breast epithelial cell line, MCF-10A.
We evaluated if generation of extra centrosomes by genetic
means will impact migration and invasion kinetics in
breast epithelial cells. To this end, we used MCF-10A cells
engineered to facilitate inducible overexpression of wildtype Plk4 or truncated Plk4 (1-608, negative control), upon
doxycycline treatment for 48 h. CA induced 48 h after
Plk4 induction was confirmed by immunofluorescence
staining for γ-tubulin (green) (data not shown) and
change in γ-tubulin levels by immunoblotting in cells

overexpressing wild-type Plk4 (denoted as Plk4 OE in
Fig. 5C, whereas no amplification was observed in cells
overexpressing truncated Plk4 (denoted as C in Fig. 5C).
We also observed a significant increase in vimentin levels
along with centrosomal proteins upon doxycycline-based
induction of CA (Fig. 5C). We then performed a classical
wound healing assay to assess the migratory capacity of
cells with amplified centrosomes (~80% cells harboring
extra centrosomes) as compared to the control cells. We
found that cells with CA filled the scratch wound in less
than half the time as control cells (28 h as compared
to 60 h) (Fig. 5D). Additionally, an increase in the
invasion capacity of wild-type Plk4 overexpressing cells
was observed in a Boyden chamber assay. Fig. 5E shows
that a significantly higher number of cells invaded the
bottom chamber of the filter after 48 h of incubation. We
also confirmed these observations by inducing centrosome
amplification via pharmacological manipulation. We
experimentally induced centrosome amplification in
MDA-MB-231 cells by aphidicolin treatment (5 μg/ml
for 48 h). Centrosome amplification upon treatment was
confirmed by immunofluorescence staining for γ-tubulin
(Suppl. Fig. 1A). An increase in the invasion capacity
of treated cells was observed via Boyden chamber assay
(Suppl. Fig. 1B).
These data collectively underscore the critical role
of centrosomes in facilitating directed cell migration

Figure 5: Cells with amplified centrosomes show higher migration. Ai, ii. Time lapse images over 18 h of GFP-centrin-MDAMB-231 cells with one (i-top panel) versus four (ii-bottom panel) centrosomes. Trajectories of 10 cells each were captured over 18 h
(6 frames/h). Data was analyzed using Volocity 3.0 software and average net displacement, displacement rate and velocity measurements
were generated for the respective cells with respect to cell centroids. Scale bar 10 μm. Quantitation of net displacement Bi. displacement
rate Bii. track velocity Biii. for cells with 1 and > 2 centrosomes are shown in bar graphs. Track velocity is the rate at which the cell traces
the entire path between point a and a’. Displacement rate is the rate at which cell covers the distance from point a to a’. C. Immunoblots
showing protein expression levels of γ-tubulin, centrin and vimentin in MCF-10A cells expressing either inducible truncated Plk4 (denoted
as C) or inducible wild-type Plk4 (denoted as Plk4 OE). D. Brightfield microscopic images showing wound healing capacity of MCF-10A
cells expressing either inducible truncated Plk4 (denoted as Control) or inducible wild-type Plk4 (denoted as Plk4 OE) at 0 h and 28 h.
Scale bar 10 μm. E. Bar graph showing the number of invaded cells in Boyden chamber assay performed with control (truncated Plk4) and
wild-type Plk4 overexpressing MCF-10A cells. CTR = centrosomes.
www.impactjournals.com/oncotarget
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and invasion. These observations lay the experimental
foundation that link CA, an important cellular feature
of certain cancers, to more aggressive phenotypes and
provide a tantalizing possibility that organellar-level
differences may serve as a risk predictor of aggressiveness
in breast cancer patients.

that supernumerary centrosomes that are tightly clustered
during interphase may appear as a large centrosome,
and thus in fact appear to be a ‘structural defect’. In
several cases, one can notice supernumerary centrosomes
with increased PCM, making it both a structural and
numerical defect. These issues render quantitation of
centrosomal defects very subjective and dependent
on the viewer’s discretion. Therefore, better methods
to systematically assess and distinguish centrosome
abnormalities are much needed. Numerical defects in
the form of centrosome amplification have been widely
described in human cancer, but not much is known about
the structural defects. It is reasonable to speculate that
both numerical and structural defects may distinctly
shape the course of tumor progression. We reason that
in low grade tumors, numerical defects that manifest
as amplified centrosomes may advantageously serve
cancer cells during an erroneous mitosis by offering
them a means to generate an array of clones that form
the basis of intratumor heterogeneity, the Holy Grail
of cancer chemotherapy. Once these heterogeneous
clones attain desirable karyotypes, we conjecture that
individual centrosomes tend to cluster which may endow
cells with cytoskeleton-derived mechanical advantages
for directional migration. This might partly explain
why certain non-invasive lesions transform into highly
aggressive tumors with metastatic capabilities while others
tend to remain indolent. This is in consonance with the
fact that an increased centrosomal complement displays
an augmented microtubule nucleation capacity [13].
We envision that a higher microtubular density in
cancer cells in conjunction with the action of the actin
cytoskeleton may provide cells with protrusion capability
for faster migration through the ECM [22]. Centrosomes
and the microtubules they nucleate together establish
the nuclear-centrosomal axis, which defines direction
of cell movement, and controls post-mitotic Golgi
reassembly [23]. Essentially, microtubules nucleated on
the juxta-centrosomal Golgi serve as tracks for Golgiderived vesicles carrying proteins essential for leading
edge protrusion, and matrix remodeling [22]. Our data
in MDA-MB-231 cells (where 20–30% of cells display
CA) showed that cells with extra centrosomes migrate
~2-fold faster than cells with normal centrosome number
(Fig. 5A, 5B). In addition to facilitating faster cellular
movement, it is likely that supernumerary centrosomes
may impart cells with an enhanced stroma-penetrating
capacity through an inventory of mechanisms including
augmentation of microtubule-dependent MMP secretion.
Currently-used prognostic indicators in breast
cancer (e.g. Ki67) do not predict metastases risk
accurately in early- tumors. Expensive commercial
multigene expression assays such as OncotypeDx
provide a “Recurrence Score” and while treatment paths
for patients with scores < 18 (low-risk) and > 31 (highrisk) are relatively unambiguous, 34% of patients with

DISCUSSION
A century ago, Theodore Boveri proposed that
subtle mitotic errors in dividing cells are responsible for
generating aneuploidy and chromosomal instability, and
thus propelling tumorigenesis [10]. This pioneering theory
originated from his observations that increased number
of centrosomes lead to multipolar mitosis and highly
aneuploid daughter cells. Since then, several landmark
studies have demonstrated that the centrosome plays an
important role in erection of a fusiform spindle apparatus
that ensures high-fidelity chromosome segregation to
produce two genetically-identical progeny cells [11, 12].
It is now well-established that abnormal number of
centrosomes most often result in aberrant mitotic divisions
and aneuploidy, all of which are frequently observed in
many solid and hematological human cancers [13–18].
In addition, chromosomal instability underlies
generation of aneuploidy over time, and has been
associated with various prognosticators in breast cancer.
All these studies point towards a strong correlation
between centrosome amplification and tumor progression,
recurrence and poor survival yet the mechanistic aspects
of this relationship have remained elusive. Recently,
Godinho et al. provided convincing cell-based evidence to
prove that centrosome amplification can cause oncogenelike effects to promote cellular invasion in mammary
epithelial cells [19]. These findings assert that cytoskeletal
modifications at the structural level driven by centrosome
amplification engenders transformation potential in normal
epithelial cells and is directly responsible for tumor
initiation and progression. This study clearly substantiates
our published hypothesis that cells endowed with extra
centrosomes possess a cytoskeletal edge over other cells,
thus imparting enhanced cell polarization, Golgi-mediated
vesicular trafficking and invasion potential, leading to
increased metastatic progression.
Indeed, a miscellany of centrosomal defects
such as increase in number, size, and atypical structure
comprise centrosome amplification. Centrosomal
amplification in human cancers is of two kinds: structural
and numerical [20, 21]. Structural defects can be due to
abnormal centriole structure and/or abnormal amount
of pericentriolar material (PCM). While detection of
alterations in centriole size is precise using centriolespecific antibody, an increased amount of PCM, detected
by a pericentriolar antibody, can present complex
ambiguous scenarios. One possibility is increased PCM,
making it a ‘true structural defect’. Another possibility is
www.impactjournals.com/oncotarget
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amplification and vimentin expression in breast cancer
patients. These data lay compelling grounds for the
exploration of centrosomal defects as cell-biological traits
of non-invasive lesions that can potentially determine
metastatic risk and meaningfully contribute towards the
dawn of precision medicine.

scores between 18–31 lack additional markers to guide
optimal [24]. Given that breast cancers harbor amplified
centrosomes, a quantitative estimation of centrosomal
abnormalities in fine-needle aspirates or paraffinembedded samples may prove to be a simple, sensitive,
and easily quantifiable risk-predicting biomarker.
Precise prognosis suffers challenges owing to
various confounding factors with bearing on breast
cancer patient outcomes such as race, age, receptorstatus, molecular signatures and so on. For instance,
among African-American women with breast cancer,
there is an estimated 20–40% chance of the breast cancer
being triple-negative [4, 25]. It is well known that TNBC
accounts for ~15% of all breast cancer in the United
States. It seems to be more common in (a) young women,
(b) women of African ancestry, and (c) individuals with
BRCA1 mutations [26]. Cancer recurs in ~30% of TNBC
patients at an early stage, typically within three to four
years following treatment. Further studies are required
to understand why premenopausal women and women in
some ethnic groups have higher rates of triple-negative
breast cancer than other groups of women, and what
mechanisms underlie the aggressive traits of TNBCs.
Such studies will be critical in order to device relevant
treatment strategies specific for the particular group pf
patients or tumor subtypes. However, finding suitable
targeting pathways in TNBC is proving to be a challenge,
particularly because these biologically aggressive tumors
do not depend on one dominant pathway, unlike ERpositive or Her2-positive tumors. Several studies have led
to the realization that TNBC tumors are a mixed bag and
this extensive heterogeneity reported in TNBC provides
a strong indication that CA that underlies chromosomal
instability driven karyotypic diversity could be the
underlying cause of the aggressive nature of this breast
cancer subtype. Recent reports focused on identifying
the key genetic and molecular features of individual
TNBC tumors led to the identification of 7 TNBC
subtypes, as follows: basal-like 1 (BL1); basal-like 2
(BL2); immunomodulatory (IM); mesenchymal (M);
mesenchymal stem–like (MSL); luminal androgen receptor
(LAR); and unstable (UNS) [27]. Such a classification
based on differential gene and molecular expression is a
significant effort in unmasking specific susceptibilities of
tumors, which can be targeted for tailored therapies. While
the enormous effort and cost associated with such gene
expression based assays limit their feasibility and prompt
use in the clinic, non-invasive centrosome-based detection
methods (e.g. in fine-needle aspirate cytology) may allow
early detection of fatal breast cancers and distinguish them
from benign forms. Since majority of breast cancers are
characterized by centrosome amplification, the extent,
severity and type of amplification can provide insights
into the metastatic propensity of certain tumors as opposed
to others. In this study, we have clearly demonstrated a
positive correlation between markers of centrosome
www.impactjournals.com/oncotarget

MATERIALs AND METHODS
In silico analysis of CAI
One channel microarray data were collected from
Gene Expression Omnibus (GEO) database and Cancer
Genome Atlas (TCGA) and processed using Robust
Multiarray (RMA) normalization, and was further used
for gene expression analysis. The lists of the GSE ID’s
are given in Supplementary table 1. Log2n transformed
expression levels of Plk4, Aurora-A, Centrin-2,
γ-tubulin and pericentrin genes were extracted from
the TCGA and GEO patients and a summation was
calculated to generate a CAI for TNBC and Non-TNBC
patients. Statistical analysis was performed using
Student’s t-test. The criterion for statistical significance
was p < 0.05.

Clinical tissue samples
Paraffin embedded slides were procured from
Emory University Hospital and Northside Hospital with
information on clinical outcomes. The Emory Institutional
Review Board (IRB) and Northside Hospital approval
was obtained for all aspects of the study. Twenty freshfrozen tissue samples for immunoblotting were procured
from Meenakshi V. Gupta, West Georgia Hospital. All the
tissue samples used were archived and de-identified, thus
no patient consent was required.

Immunofluorescence, imaging and scoring
Tissue slides were de-paraffinized by baking
at 67°C for 2 h followed by 3 xylene washes and
rehydrated in a series of ethanol baths (100%, 95%,
70% and 50%). Antigen retrieval was performed by
citrate buffer (pH 6.0) in a pressure cooker for 3min.
Primary antibody incubation was done overnight against
γ-tubulin (1:1000) at 4°C. The samples were incubated
with secondary antibody (Alexa-488 anti-mouse) at
37°C for 2 h. Samples were washed 3x with PBS and
then mounted with Prolong-Gold antifade reagent that
contained DAPI (Invitrogen). Tissue samples were
imaged using the Zeiss LSM 700 Confocal microscope
(Oberkochen, Germany) and images were processed with
Zen software (Oberkochen, Germany). Percentage cells
with centrosomal abnormality were quantitated from
10 randomly selected fields per sample (500 cells counted
for each sample).
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Immunohistochemistry and scoring

Antibodies against γ-tubulin, α-tubulin were incubated
with coverslips for 1 h at 37°C at the dilution 1:2000.The
cells were washed with 2% bovine serum albumin/PBS
for 10 min at room temperature before incubating with a
1:2000 dilution of Alexa 488- or 555-conjugated secondary
antibodies Invitrogen (Carlsbad, CA, USA). Antibodies
against γ- tubulin, α-tubulin and vimentin were from
Sigma (St. Louis, MO, USA), Aurora-A, Plk4 and β-actin
were from cell signaling, Centrin-2 and Cyclin E from
Santacruz and Pericentrin-2 from Abcam. Horseradish
peroxidase-conjugated secondary antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Samples were processed in the same way till antigen
retrieval as mentioned above in Immunofluorescence
section. Tissues were then immunostained for vimentin,
Plk4 and Aurora-A. To perform enzymatic antibody
detection, Universal LSAB + kit/HRP (DAKO, CA, USA)
was used. A relative intensity score was represented as
0 = none, 1 = low, 2 = moderate, or 3 = high and frequency
score was depicted as the percentage of cell nuclei or
cytoplasm demonstrating vimentin positivity (i.e. a score
of 1, 2, or 3). The product of intensity and frequency was
measured as weighted index (WI) for both the nucleus and
cytoplasm.

Boyden chamber assay

Three-dimensional volume measurement

MCF-10A cells overexpressing inducible Plk4 or
truncated version of Plk4 (1-608) were collected after 24 h
transfection and resuspended in media at 5 × 104 cells/ml
density. Transmigration assay was carried out in a Boyden
chamber system. Cells that had migrated to the bottom
surface of the filter were fixed with 70% methanol, stained
with crystal violet, and counted under a microscope in
10 randomly selected fields at 20X magnification (Zeiss
Axioplan).

10–15 fields of view within the stained tissue
were imaged via laser scanning confocal microscopy
(Zeiss, Oberkochen, Germany) and for each field, optical
sections of 0.5 um thickness each are acquired. For
each field of view, the optical sections are stacked to
produce a “maximum intensity projection image”. The
raw confocal images are then opened in a 3-D volume
rendering software (Zeiss, Oberkochen, Germany) for
determining the volumes of each centrosome present in
each microscopic field. The volume range for a normal
centrosome is determined by analyzing the volumes of
at least 500 centrosomes from normal tissue of 3 normal
breast tissues. The smallest and the largest value for
centrosomal volume provide the normal centrosome
volume range for that tissue.

Time-lapse imaging
Stably transfected centrin-GFP MDA-MB-231
cells were plated at 60% confluence on Matek cell
culture plates. Cells were then imaged using time-lapse
microscopy at 40X magnification on PerkinElmer Ultra
View ERS spinning disc microscope (Waltham, MA,
USA). GFP images were captured at multiple points every
10 min for 18 h. Captured images from each experiment
were analyzed using Volocity software (Improvision
Coverty, UK).

Cell culture
MCF-7, MDA-MB-231 and MDA-MB-468 cells
were purchased from ATCC. MCF-7cells were grown in
MEM, MDA-MB-231 and MDA-MB-468 were grown in
DMEM supplemented with 10% Hyclone Fetal Bovine
serum and 1% penicillin/streptomycin and MCF-10-A
were grown in MGEM (Lonza). All cell lines were
maintained in 5% CO2 atmosphere at 37°C.

Statistical analysis
Statistical analysis was performed using student t-test
and ANOVA, where the criteria for statistical significance
was p < 0.05. For ideal thresholds, the FINDCUT macro
developed by Jayawant N. Mandrekar et al. from Mayo
Clinic (http://www2.sas.com/proceedings/sugi28/261-28.
pdf) was used, which identifies the optimal cut off point for
a continuous variable that predicts time to event outcomes,
in our case CAI and %CA.

Cellular protein preparation, Immunoblot
analysis, Immunofluorescence and antibodies
Protein lysates were prepared from ~70% confluence
cells and frozen tissue samples (sonicated). Briefly, PAGE
was used to resolve the proteins and transferred on to
PVDF membrane (Millipore). Pierce ECL detection kit
(Thermo Scientific) was used to visualize the immunereactive bands corresponding to respective primary
antibodies. β-actin was used as loading control. For
immunofluorescence staining, cells were grown on glass
coverslips and fixed with ice cold methanol for 10 min.
Blocking was done by incubating with 2% bovine serum
albumin/PBS.0.05% Triton X-100 at 37°C for 1 h. Primary
www.impactjournals.com/oncotarget
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